Arylalkylamine Drugs of Abuse An Overview of Drug Discrimination Studies

@article{Glennon1999ArylalkylamineDO,
  title={Arylalkylamine Drugs of Abuse An Overview of Drug Discrimination Studies},
  author={Richard A Glennon},
  journal={Pharmacology Biochemistry and Behavior},
  year={1999},
  volume={64},
  pages={251-256}
}
  • R. Glennon
  • Published 1 October 1999
  • Chemistry
  • Pharmacology Biochemistry and Behavior

Figures and Tables from this paper

Amphetamine Derivatives as Monoamine Oxidase Inhibitors

TLDR
This work reviews how structural modifications on the aromatic ring, the amino group and/or the aliphatic side chain of the parent scaffold, modulate the enzyme inhibitory properties of hundreds of amphetamine derivatives.

Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions

  • A. Yu
  • Biology
    The AAPS Journal
  • 2008
TLDR
An important role for polymorphic cytochrome P450 2D6 (CYP2D 6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP1D6 polymorphism may represent an additional risk factor in the use of these IAAdrugs.

The behavioral pharmacology of hallucinogens.

Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines

TLDR
Hallucinogen-induced stimulus control provides a unique behavioral tool for the prediction of subjective effects in man and for the elucidation of the pharmacological mechanisms of the action of these agents.

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

TOWARDS UNDERSTANDING THE MECHANISM OF ACTION OF ABUSED CATHINONES

TLDR
Cathinone and methcathinone analogs as well as their amphetamine and methamphetamine counterparts were synthesized and examined at the hDAT expressed in Xenopus oocytes, and one of the two major constituents of ‘bath salts’ produced an electrophysiological signature similar to the dopamine releasing agent S(+)-amphetamine.

Abuse Liability Profile of Three Substituted Tryptamines

TLDR
DIPT and 5-MeO-DET may have abuse liability similar to known hallucinogens and may be hazardous because high doses produced activity and lethality, but were not similar to those of psychostimulants.

References

SHOWING 1-10 OF 34 REFERENCES

Structure-activity relationships of MDMA-like substances.

TLDR
This chapter will relate recent fmdings with respect to the potential dangers attendant on the use of MDMA and explore its pharmacological properties.

The pharmacology of hallucinogens.

TLDR
In the context of the yawning abyss of ignorance and speculation which separates biochemical and behavioural data, the contribution of these few observations on psychotomimetics may be regarded as vanishingly small.

Discriminative stimulus properties of amphetamine, cathinone, and related agents.

TLDR
The possibility that the AMPH cue may generate false positives in screening for drug abuse potential needs to be evaluated and the inconsistent findings in substitution studies with nisoxetine need to be addressed.

PHARMACOLOGICAL ASPECTS OF DRUG DEPENDENCE.

Discriminative stimulus effects of S(−)–methcathinone (CAT): a potent stimulant drug of abuse

TLDR
It is concluded that S(−)-methcathinone is a very potent CNS stimulant, which appears to produce its stimulus effect, at least in part, via a dopaminergic mechanism.

Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors

TLDR
The present study examined and compared the binding of 17 phenylisopropylamines at human 5- HT2A, 5-HT2B, and 5-Hat2C receptors and found a significant correlation between 5-ht2B receptor affinity and human hallucinogenic potency.

Discriminative Stimulus Properties of (−)Ephedrine